Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,816.89
(
-0.11%
)
US TECH 100
24,499.60
(
0.38%
)
Dow Jones
47,916.57
(
-0.56%
)
Brent Oil
92.41
(
0.00%
)
Bitcoin
70,813.01
(
-3.10%
)
News Focus
News Focus
Post# of 257391
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122862
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 238530

Tuesday, 06/29/2021 9:24:34 AM

Tuesday, June 29, 2021 9:24:34 AM

Post# of 257391
ABUS starts_what_looks_like_another_futile_combination_trial: AB-729; Antios Therapeutics’ ATI-2173, a nucleotide polymerase inhibitor; and tenofovir (another nuke):

https://finance.yahoo.com/news/arbutus-biopharma-antios-therapeutics-announce-110000743.html

ABUS is already conducting a combination trial of AB-729 with ASMB’s ABI-H0731 that I would characterize as futile insofar as ABI-H0731 is effectively an obsolete compound (#msg-157913492, #msg-162149575).

All told, I would say that ABUS is flailing.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today